This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The country’s health metrics, such as the growing burden of non-communicable diseases, rising life expectancy, malnutrition, and air pollution, present a further scope for innovations in life sciences to strengthen healthcare delivery estimated to reach $60 billion by FY 2028 (1).
The new, free of charge section makes tailored information about wet AMD available to the approximately 20 million people worldwide with wet AMD along with tools to help them stay on track with treatment and in communication with their doctors. The post Novartis taps smartpatient for app to support wet AMD patients appeared first on.
Recruiting and retaining talent is one of the biggest challenges facing the industry now through 2028, as the US Bureau of Labor Statistics expects life, physical, and social sciences to grow 7%. Investing in technology for onboarding, training, and employee communication can help cut expenses and positively impact engagement.
According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. Reuters reported that GSK had acknowledged the fall in supply and said it was pursuing plans to address the deficit.
Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028. The compounds require special handling due to their cytotoxicity in the NCEs and investigational new drug applications (INDs). 1 What are the challenges companies face in identifying and assessing the toxicity and potency of HPAPIs?
In 2021, a pilot communications programme from AstraZeneca UK and the NHS was launched in four locations across England. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028. It exists in multiple areas across multiple organisations.
Furthermore, to ensure that these measures are transparent and accessible to consumers, we encourage CMS to require insurers to clearly communicate any available payment threshold options to their members. link] reports/the-use-of-medicines-in-the-us-2024/the-use-of-medicines-in-the-us-2024-usage-and-spending- trends-and-outlook-to-2028.pdf.
With two of its upcoming drug launches already pipped to be blockbusters by 2028, smart manoeuvres in the immunology space could help Lilly close the gap between itself and other companies like Johnson & Johnson. Please check your email to download the Report.
As it stands, GlobalData analysis predicts that Keytruda’s yearly revenue will hit almost $35bn in 2028, up from $21bn in 2022. It showed promising event-free survival (EFS) of 62.4% in the Keytruda arm, with median EFS not being met. Free Report How is the Biopharmaceutical industry evolving?
The district court had previously blocked Sandoz and Zydus from producing, selling, offering to sell, or importing generic versions of Otezla until February 2028. The April 19 ruling affirms a permanent injunction made by the US District Court for the District of New Jersey in September 2021. billion worth of the drug worldwide.
billion by 2028. Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022. GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6
The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. As part of the decision-making process, they may request further evidence. By 2030, JCAs will be carried out on all medicinal products with an EMA-issued MA.
The NHC also emphasizes the importance of clear communication and transition planning to minimize disruptions. Equally critical is clear and accessible communication with beneficiaries. 3 American Medical Association. Prior Authorization Physician Survey Report. link] assn.org/system/files/prior-authorization-survey.pdf.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content